WU F, ZHAO S, YU B, et al. A New Coronavirus Associated with Human Respiratory Disease in China[J/OL]. Nature, 2020(2020-02-03)[2020-02-28] https: //www.nature.xilesou.top/articles/s41586-020-2008-3.
ZHOU P, YANG X L, WANG X G, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin[J/OL]. Nature, 2020(2020-02-03)[2020-03-01] https://www.nature.xilesou.top/articles/s41586-020-2012-7?TB_iframe=true&width=370.8&height=658.8.
ZHU N, ZHANG D Y, WANG W L, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. New England Journal of Medicine, 2020, 382(8):727-733.
VELAVAN T P, MEYER C G. Tropical Medicine & amp; International Health March 2020[J]. Tropical Medicine & International Health, 2020, 25(3):277.
RUBIN E J, BADEN L R, MORRISSEY S, et al. Medical Journals and the 2019-nCoV Outbreak[J]. New England Journal of Medicine, 2020, 382(9):866.
PEIRIS J, LAI S T, POON L, et al. Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome[J]. The Lancet, 2003, 361(9366):1319-1325.
KAHN J S, MCINTOSH K. History and Recent Advances in Coronavirus Discovery[J]. The Pediatric Infectious Disease Journal, 2005, 24(S):223-227.
LU R, ZHAO X, LI J, et al. Genomic Characterization and Epidemiology of 2019-Novel Coronavirus:Implications for Virusorigins and Receptor Binding[J]. Lancet, 2020, 395(10224):565-574.
GUARNER J. Three Emerging Coronaviruses in Two Decades[J]. American Journal of Clinical Pathology, 2020, 153(4):420-421.
CHAN JASPERF W, YUAN S F, KOK K H, et al. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-person Transmission:a Study of a Family Cluster[J]. The Lancet, 2020, 395(10223):514-523.
国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03)[2020-03-03] http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
WANG B X, FISH E N. Global Virus Outbreaks:Interferons as 1st Responders[J]. Seminars in Immunology, 2019, 43:101300.
申昆玲, 张国成, 尚云晓, 等.重组人干扰素-α1b在儿科的临床应用专家共识[J].中华实用儿科临床杂志, 2015, 30(16):1214-1219.
ROUZIOUX C. Prevention of Maternal HIV Transmission. Practical Guidelines[J]. Drugs, 1995, 49(1):17-24.
CHU C M. Role of Lopinavir/ritonavir in the Treatment of SARS:Initial Virological and Clinical Findings[J]. Thorax, 2004, 59(3):252-256.
ARABI Y M, ASIRI A Y, ASSIRI, A M, et al. Treatment of Middle East Respiratory Syndrome with a Combination of Lopinavir/ritonavir and Interferon-β1b (MIRACLE Trial):Statistical Analysis Plan for a Recursive Two-stage Group Sequential Randomized Controlled Trial[J]. Trials, 2020, 21(1):8.
XU X W. Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) Outside of Wuhan, China: Retrospective Case Series[J/OL]. BMJ, 2020(2020-02-19)[2020-03-01] https://www.bmj.com/content/368/bmj.m606.full
马攀, 贾运涛.基于FDA不良事件数据库对洛匹那韦/利托那韦安全信号的检测与分析[J].中国现代应用药学, 2020, 37(4):22-25.
陈军, 凌云, 席秀红, 等.洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J]. (2020-02-21)[2020-03-01] http://rs.yiigle.com/yufabiao/1182592.htm.
ERIC A F S, BONT L, MANZONI P, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children[J]. Infectious Diseases & Therapy, 2018, 7(1):87-120.
SAIJO M, MORIKAWA S, FUKUSHI S, et al. Inhibitory Effect of Mizoribine and Ribavirin on the Replication of Severe Acute Respiratory Syndrome (SARS)-associated Coronavirus[J]. Antiviral Research, 2005, 66(2/3):159-163. doi: 10.1016/j.antiviral.2005.01.003
AL-TAWFIQ J A, MOMATTIN H, DIB J, et al. Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus:an Observational Study[J]. International Journal of Infectious Diseases, 2014, 20:42-46.
TSANG K W, HO P L, OOI G C, et al. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong[J]. New England Journal of Medicine, 2003, 348(20):1977-1985.
JANG T N, YEH D Y, SHEN S H, et al. Severe Acute Respiratory Syndrome in Taiwan:Analysis of Epidemiological Characteristics in 29 Cases[J]. Journal of Infection, 2004, 48(1):23-31. doi: 10.1016/j.jinf.2003.09.004
BOOTH C M. Clinical Features and Short-Term Outcomes of 144 Patients with SARS in the Greater Toronto Area[J]. JAMA, 2003, 289(21):2801-2809.
BARNARD D L, DAY C W, BAILEY K, et al. Enhancement of the Infectivity of SARS-CoV in BALB/c Mice by IMP Dehydrogenase Inhibitors, Including Ribavirin[J]. Antiviral Res, 2006, 71(1):53-63.
SOO Y O Y, CHENG Y, WONG R, et al. Retrospective Comparison of Convalescent Plasma with Continuing High-dose Methylprednisolone Treatment in SARS Patients[J]. Clinical Microbiology and Infection, 2004, 10(7):676-678.
LU Q B, ZHANG S Y, CUI N, et al. Common Adverse Events Associated with Ribavirin Therapy for Severe Fever with Thrombocytopenia Syndrome[J]. Antiviral Research, 2015, 119:19-22.
TONG M J, CHANG P W, HUYNH T T, et al. Adverse Events Associated with Ribavirin in Sofosbuvir-based Therapies for Patients with Chronic Hepatitis C:a Community Practice Experience[J]. Journal of Digestive Diseases, 2016, 17(2):113-121.
国家药典委员会.中华人民共和国药典临床用药须知:化学药和生物制品卷[M].北京:中国医药科技出版社, 2011.
VINCENT M, BERGERON E, BENJANNET S, et al. Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread[J]. Virology Journal, 2005, 2(1):69.
YANG Z Y, HUANG Y, GANESH L, et al. PH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN[J]. Journal of Virology, 2004, 78(11):5642-5650.
DE WILDE A H, JOCHMANS D, POSTHUMA C C, et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture[J]. Antimicrobial Agents and Chemotherapy, 2014, 58(8):4875-4884.
WANG M L, CAO R Y, ZHANG L K, et al. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro[J]. Cell Research, 2020, 30:269-271.
RIOU B, BARRIOT P, RIMAILHO A, et al. Treatment of Severe Chloroquine Poisoning[J]. New England Journal of Medicine, 1988, 318(1):1-6.
DUCHARME J, FARINOTTI R. Clinical Pharmacokinetics and Metabolism of Chloroquine[J]. Clinical Pharmacokinetics, 1996, 31(4):257-274.
NICHOLAS M H, AHMED A M, MARTIN M K. Chloroquine and Hydroxychloroquine Toxicity[J]. Archives of Ophthalmology, 2011, 129(11):1506-1507.
BORISKIN Y, LENEVA I, PECHEUR E I, et al. Arbidol:a Broad-Spectrum Antiviral Compound that Blocks Viral Fusion[J]. Current Medicinal Chemistry, 2008, 15(10):997-1005.
PÉCHEUR E I, BORISEVICH V, HALFMANN P, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses[J]. Journal of Virology, 2016, 90(6):3086-3092.
WANG Z W, CHEN X R, LU Y F, et al. Clinical Characteristics and Therapeutic Procedure for Four Cases with 2019 Novel Coronavirus Pneumonia Receiving Combined Chinese and Western Medicine Treatment[J/OL]. BioScience Trends, 2020(2020-02-09)[2020-03-01] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=32037389&query_hl=1.
PSHENICHNAYA N Y, BULGAKOVA V A, LVOV N I, et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)[J]. Terapevticheskii arkhiv, 2019, 91(3):56-63.
LAI C C, SHIH T P, KO W C, et al. Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) and Coronavirus Disease-2019(COVID-19): The Epidemic and the Challenges[J/OL]. Int J Antimicrob Agents, 2020(2020-02-18)[2020-03-01] https://sciencedirect.xilesou.top/science/article/pii/S0924857920300674.
JANOWSKI A B, DUDLEY H, WANG D. Antiviral Activity of Ribavirin and Favipiravir Against Human Astroviruses[J/OL]. Journal of Clinical Virology, 2020(2020-02-18)[2020-03-02] https://sciencedirect.xilesou.top/science/article/abs/pii/S138665321930277X.
XIA S, ZHU Y, LIU M Q, et al. Fusion Mechanism of 2019-nCoV and Fusion Inhibitors Targeting HR1 Domain in Spike Protein[J/OL]. Cellular & Molecular Immunology, 2020(2020-02-11)[2020-03-02] https://www.nature.xilesou.top/articles/s41423-020-0374-2.
XIA S, YAN L, XU W, et al. A Pan-Coronavirus Fusion Inhibitor Targeting the HR1 Domain of Human Coronavirus Spike[J]. Science Advances, 2019, 5(4):4580.